Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Ulcerative Colitis | Research

Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea

Authors: Hyuk Yoon, Young Soo Park, Jeong Eun Shin, Byong Duk Ye, Chang Soo Eun, Soon Man Yoon, Jae Myung Cha, You Sun Kim, Kyu Chan Huh, Young Sook Park, Jae Hee Cheon, Eun Suk Jung, Youngdoe Kim, Su Young Jung

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Many patients with ulcerative colitis (UC) gain weight after treatment. However, the clinical significance of weight gain in these patients remains unclear. This study aimed to evaluate body weight changes after treatment in patients newly diagnosed with moderate-to-severe UC and their effects on patients’ prognosis.

Methods

The change in weight between diagnosis and 1 year after treatment in 212 patients enrolled in the MOSAIK cohort (mean age, 40 years; males, 60%) was analyzed. Significant weight gain was defined as a weight increase of ≥ 5% from the baseline at 1 year. Factors associated with significant weight gain and the effect of significant weight gain on the risk of major adverse outcomes (clinical relapse, hospitalization, and new use of steroids or biologics) during a follow-up period of 20 months were evaluated.

Results

Mean weight gain at 1 year was 1.7 ± 4.2 kg. The proportion of overweight/obese patients increased by 9.0% from 37.9% to 46.9%. Thirty-two percent had significant weight gain; extensive colitis at diagnosis was the only factor associated with significant weight gain (odds ratio 6.5, 95% confidence interval 1.4–31.0, p = 0.006). In multivariable analysis, significant weight gain was not associated with the risk of major adverse outcomes. Weight loss symptoms at diagnosis were associated with an increased risk for new steroid use after 1 year.

Conclusions

Approximately one-third of patients with moderate-to-severe UC had significant weight gain after 1 year of treatment. However, significant weight gain was not associated with the patient’s prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jensen CB, Angquist LH, Mendall MA, Sorensen TIA, Baker JL, Jess T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. Am J Gastroenterol. 2018;113(5):694–701.CrossRefPubMed Jensen CB, Angquist LH, Mendall MA, Sorensen TIA, Baker JL, Jess T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. Am J Gastroenterol. 2018;113(5):694–701.CrossRefPubMed
2.
go back to reference Chan SSM, Chen Y, Casey K, Olen O, Ludvigsson JF, Carbonnel F, Oldenburg B, Gunter MJ, Tjonneland A, Grip O, et al. Obesity is associated with increased risk of Crohn’s disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol. 2022;20(5):1048–58.CrossRefPubMed Chan SSM, Chen Y, Casey K, Olen O, Ludvigsson JF, Carbonnel F, Oldenburg B, Gunter MJ, Tjonneland A, Grip O, et al. Obesity is associated with increased risk of Crohn’s disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol. 2022;20(5):1048–58.CrossRefPubMed
3.
go back to reference Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110–21.CrossRefPubMed Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110–21.CrossRefPubMed
4.
go back to reference Johnson AM, Harmsen WS, Aniwan S, Tremaine WJ, Abu Dayyeh BK, Loftus EV. Prevalence and impact of obesity on disease-specific outcomes in a population-based cohort of patients with ulcerative colitis. J Crohns Colitis. 2021;15(11):1816–23.CrossRefPubMedPubMedCentral Johnson AM, Harmsen WS, Aniwan S, Tremaine WJ, Abu Dayyeh BK, Loftus EV. Prevalence and impact of obesity on disease-specific outcomes in a population-based cohort of patients with ulcerative colitis. J Crohns Colitis. 2021;15(11):1816–23.CrossRefPubMedPubMedCentral
5.
go back to reference Jiang K, Chen B, Lou D, Zhang M, Shi Y, Dai W, Shen J, Zhou B, Hu J. Systematic review and meta-analysis: association between obesity/overweight and surgical complications in IBD. Int J Colorectal Dis. 2022;37(7):1485–96.CrossRefPubMedPubMedCentral Jiang K, Chen B, Lou D, Zhang M, Shi Y, Dai W, Shen J, Zhou B, Hu J. Systematic review and meta-analysis: association between obesity/overweight and surgical complications in IBD. Int J Colorectal Dis. 2022;37(7):1485–96.CrossRefPubMedPubMedCentral
6.
go back to reference Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123.CrossRefPubMedPubMedCentral Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123.CrossRefPubMedPubMedCentral
7.
go back to reference Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47(11):1472–9.CrossRefPubMedPubMedCentral Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47(11):1472–9.CrossRefPubMedPubMedCentral
8.
go back to reference Elsherif Y, Alexakis C, Mendall M. Determinants of weight loss prior to diagnosis in inflammatory bowel disease: a retrospective observational study. Gastroenterol Res Pract. 2014;2014:762191.CrossRefPubMedPubMedCentral Elsherif Y, Alexakis C, Mendall M. Determinants of weight loss prior to diagnosis in inflammatory bowel disease: a retrospective observational study. Gastroenterol Res Pract. 2014;2014:762191.CrossRefPubMedPubMedCentral
9.
go back to reference Haas L, Chevalier R, Major BT, Enders F, Kumar S, Tung J. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3110–6.CrossRefPubMed Haas L, Chevalier R, Major BT, Enders F, Kumar S, Tung J. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3110–6.CrossRefPubMed
10.
go back to reference Lepp J, Hoog C, Forsell A, Fyrhake U, Lordal M, Almer S. Rapid weight gain in infliximab treated Crohn’s disease patients is sustained over time: real-life data over 12 months. Scand J Gastroenterol. 2020;55(12):1411–8.CrossRefPubMed Lepp J, Hoog C, Forsell A, Fyrhake U, Lordal M, Almer S. Rapid weight gain in infliximab treated Crohn’s disease patients is sustained over time: real-life data over 12 months. Scand J Gastroenterol. 2020;55(12):1411–8.CrossRefPubMed
11.
go back to reference Winter RW, Friedman S, Nielsen J, Kjeldsen J, Norgard BM, Larsen MD. Infliximab is not associated with a general long-term weight gain in patients with inflammatory bowel disease: a Nationwide Study. Am J Gastroenterol. 2022;117(5):777–84.CrossRefPubMed Winter RW, Friedman S, Nielsen J, Kjeldsen J, Norgard BM, Larsen MD. Infliximab is not associated with a general long-term weight gain in patients with inflammatory bowel disease: a Nationwide Study. Am J Gastroenterol. 2022;117(5):777–84.CrossRefPubMed
12.
go back to reference Lee CK, Lee KM, Park DI, Jung SA, Jeen YT, Park YS, Kim HJ. Diseases MsgotKAftSoI: a new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study. Intest Res. 2019;17(1):1–5.CrossRefPubMedPubMedCentral Lee CK, Lee KM, Park DI, Jung SA, Jeen YT, Park YS, Kim HJ. Diseases MsgotKAftSoI: a new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study. Intest Res. 2019;17(1):1–5.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a phase 4, UK, open label, single arm study on its utilization and impact in ulcerative colitis). BMJ Open Gastroenterol. 2018;5(1):e000212.CrossRefPubMedPubMedCentral Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a phase 4, UK, open label, single arm study on its utilization and impact in ulcerative colitis). BMJ Open Gastroenterol. 2018;5(1):e000212.CrossRefPubMedPubMedCentral
15.
go back to reference Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D’Haens G, Sandborn WJ, et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018;16(5):637–647e613.CrossRefPubMed Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D’Haens G, Sandborn WJ, et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018;16(5):637–647e613.CrossRefPubMed
16.
go back to reference Yang YS, Han BD, Han K, Jung JH, Son JW. Taskforce Team of the obesity fact sheet of the Korean Society for the study of O: obesity fact sheet in Korea, 2021: Trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr. 2022;31(2):169–77.CrossRefPubMedPubMedCentral Yang YS, Han BD, Han K, Jung JH, Son JW. Taskforce Team of the obesity fact sheet of the Korean Society for the study of O: obesity fact sheet in Korea, 2021: Trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr. 2022;31(2):169–77.CrossRefPubMedPubMedCentral
17.
go back to reference Mazhar F, Battini V, Pozzi M, Invernizzi E, Mosini G, Gringeri M, Capuano A, Scavone C, Radice S, Clementi E, et al. Changes in anthropometric parameters after Anti-TNFalpha therapy in inflammatory bowel disease: a systematic review and Meta-analysis. BioDrugs. 2020;34(5):649–68.CrossRefPubMedPubMedCentral Mazhar F, Battini V, Pozzi M, Invernizzi E, Mosini G, Gringeri M, Capuano A, Scavone C, Radice S, Clementi E, et al. Changes in anthropometric parameters after Anti-TNFalpha therapy in inflammatory bowel disease: a systematic review and Meta-analysis. BioDrugs. 2020;34(5):649–68.CrossRefPubMedPubMedCentral
18.
go back to reference Lim Z, Welman CJ, Raymond W, Thin L. The Effect of Adiposity on Anti-tumor Necrosis factor-alpha levels and loss of response in Crohn’s disease patients. Clin Transl Gastroenterol. 2020;11(9):e00233.CrossRefPubMedPubMedCentral Lim Z, Welman CJ, Raymond W, Thin L. The Effect of Adiposity on Anti-tumor Necrosis factor-alpha levels and loss of response in Crohn’s disease patients. Clin Transl Gastroenterol. 2020;11(9):e00233.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
Authors
Hyuk Yoon
Young Soo Park
Jeong Eun Shin
Byong Duk Ye
Chang Soo Eun
Soon Man Yoon
Jae Myung Cha
You Sun Kim
Kyu Chan Huh
Young Sook Park
Jae Hee Cheon
Eun Suk Jung
Youngdoe Kim
Su Young Jung
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03008-7

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.